INS and metabolic dysfunction-associated steatotic liver disease: In 2013, Mudaliar et al. first reported that Obeticholic acid treatment led to improved insulin sensitivity, suppressed hepatic inflammation and reduced fibrosis in patients with NAFLD [117].